^
Association details:
| Biomarker: | FGFR3-TACC3 fusion |
|---|---|
| Cancer: | Urothelial Cancer |
| Drug: | zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations
Published date:
05/01/2019
Excerpt:
Among 10 patients with confirmed FGFR fusions treated at doses ≥60 mg/day, 3 achieved PRs and 5 disease stabilization (Fig. 3).
DOI:
10.1158/1078-0432.CCR-18-1959
